"It's so important to always have advocates involved because it allows us to ask those questions to researchers like 'how will this help?'" - Komen patient advocate Bob Ritter shares his thoughts on all the research updates coming from @sabcs.bsky.social #SABCS

🔬 We’re watching the science at #SABCS25. Komen Scholar Susan Domchek, M.D., is excited about the WISDOM trial using genetics & polygenic risk scores to personalize screening. @sabcs.bsky.social

📖 Read more: https://www.komen.org/blog/sabcs-watch-2025/

🚀 At #SABCS25, Ben Park, MD, PhD showed how cell signals go "off the rails" in breast cancer and how his groundbreaking work with cfDNA is changing care by helping earlier detection, better treatment tracking, and spotting metastasis sooner. @sabcs.bsky.social

At #SABCS25, Kevin Punie MD presented on ASCENT-03 patient-reported outcomes: In untreated advanced TNBC not eligible for immunotherapy, sacituzumab govitecan helped patients maintain physical activity and overall well-being better than chemo @sabcs.bsky.social

🩺🧬 Shanu Modi, MD shared DESTINY-Breast11 patient-reported outcomes: In high-risk HER2+ early breast cancer, T-DXd–based pre-surgery therapy helped more patients keep up physical functioning & daily activities vs ddAC-THP, with overall manageable side effects #SABCS25

Another DESTINY-Breast09 update from Mothaffar Rimawi MD at #SABCS25: in HER2+ advanced breast cancer, first-line T-DXd + pertuzumab kept pain and daily functioning similar to standard THP, with more stomach issues but fewer skin and swelling symptoms 🩺📈 @sabcs.bsky.social

At #SABCS25, Jean Wright MD presented results from RadComp: In locally advanced breast cancer, proton radiation therapy gave lower average doses to the heart than photon RT. 💓 At 6 months, heart-related quality of life looked similar overall, with fatigue back to baseline @sabcs.bsky.social

At #SABCS25, Dr. Curigliano shared DESTINY-Breast11 data in high-risk HER2+ early breast cancer: T-DXd–based neoadjuvant regimens showed a more favorable safety profile, with fewer serious toxicities compared with ddAC-THP, while keeping side effects manageable 🩺🧬 @sabcs.bsky.social

💡 Komen Scholar Ben Park MD shares some hot topics at #SABCS25, including blood tests (liquid biopsies) that could transform how we detect and track #breastcancer.

📖 Read more about what we're watching @sabcs.bsky.social here: https://www.komen.org/blog/sabcs-watch-2025/

We’re tracking the biggest updates from #SABCS25, from liquid biopsies to genetics-guided screening🧬

#Breastcancer experts & MD’s: Ben Park, Reshma Jagsi & Susan Domchek shared what they’re watching & why it matters for patients in our blog: https://www.komen.org/blog/sabcs-watch-2025/ 💬

Excited for #SABCS25! My first time attending as a scientific communications manager at
@susangkomen.bsky.social and as a non-academic. I will be tuning in virtually and sharing highlights. The Komen account will also be sharing live tweets if you'd like to follow along! 🧬🔬

Partners in Progress: This #SABCS25 Plenary Lecture will showcase how patients and advocates have expanded their roles in every stage of breast cancer research—including clinical trial design. Learn more in SABCS Meeting News:
buff.ly/yKwCDRx

Figured I would put this out there.

TransGENIC mice are NOT TransGENDER mice.

TransGENIC refers to an organism or cell whose genome has been genetically altered.

We use them to model human diseases & develop new treatments.

This is yet another attempt to push anti-trans & anti-science rhetoric.

I can’t believe this needs to be said.

TransGENIC mice

are not

TransGENDER mice

Transgenic mice are widely used in cancer research to study tumor development, genetic mutations, and potential treatments. TRANSGENIC

Iowa has the second highest incidence rate of cancer in the country, and it is already feeling Trump's cuts to the workforce and research institutions trying to solve the rural cancer problem.

A federal judge in San Francisco issued a temporary restraining order on the Trump administration's firings of thousands of probationary employees, calling the actions illegal.